Serplulimab

Generic Name
Serplulimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2231029-82-4
Unique Ingredient Identifier
S3GQZ2K36V
Indication

用于经过标准治疗失败的、不可切除或转移性高度微卫星不稳定型（MSI-H）成人晚期实体瘤患者。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors

First Posted Date
2024-12-11
Last Posted Date
2024-12-11
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
134
Registration Number
NCT06727617
Locations
🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Peking University Shenzhen Hospital
Target Recruit Count
200
Registration Number
NCT06692491

Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Fujian Medical University Union Hospital
Target Recruit Count
90
Registration Number
NCT06601309
Locations
🇨🇳

Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

First Posted Date
2024-07-31
Last Posted Date
2024-07-31
Lead Sponsor
RenJi Hospital
Target Recruit Count
80
Registration Number
NCT06531291
Locations
🇨🇳

Renji hospital, Shanghai, Shanghai, China

Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

First Posted Date
2024-07-11
Last Posted Date
2024-07-12
Lead Sponsor
Guangzhou Institute of Respiratory Disease
Target Recruit Count
30
Registration Number
NCT06497530

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Phase 2
Recruiting
Conditions
Cervical Cancer
Interventions
Drug: Nituzumab
Drug: Serplulimab
First Posted Date
2024-06-12
Last Posted Date
2024-06-12
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
37
Registration Number
NCT06455072
Locations
🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

First Posted Date
2024-06-03
Last Posted Date
2024-06-03
Lead Sponsor
The First Affiliated Hospital of Zhengzhou University
Target Recruit Count
42
Registration Number
NCT06439550

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

First Posted Date
2024-05-30
Last Posted Date
2024-05-30
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
60
Registration Number
NCT06433869
Locations
🇨🇳

Cancer center of SunYat-sen University, Guangzhou, Guangdong, China

🇨🇳

Zhang Dongsheng, Guangzhou, China

Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

First Posted Date
2024-05-21
Last Posted Date
2024-05-21
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
37
Registration Number
NCT06422858
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

First Posted Date
2024-05-17
Last Posted Date
2024-05-17
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
240
Registration Number
NCT06419673
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy